Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib in Advanced Breast Cancer with Visceral Crisis
NCT05431504Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jun 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dalpiciclib in breast cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: 6-month Overall Survival rate. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05431504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05431504.